PMID- 31240297
OWN - NLM
STAT- In-Data-Review
LR  - 20190910
IS  - 1938-3207 (Electronic)
IS  - 0002-9165 (Linking)
VI  - 110
IP  - 3
DP  - 2019 Sep 1
TI  - Metabolically healthy obesity: what's in a name?
PG  - 533-539
LID - 10.1093/ajcn/nqz133 [doi]
AB  - Metabolically healthy obesity refers to an obesity phenotype with no or little
      evidence of metabolic dysfunction. Lower liver fat content and visceral adipose
      tissue, greater insulin sensitivity and secretion, greater cardiorespiratory
      fitness, and a predominantly lower body (i.e., leg) fat deposition are key
      physiological traits of a metabolically healthy phenotype. About 35% of all
      subjects with obesity are metabolically healthy. These individuals have
      approximately half the risk of developing type 2 diabetes and cardiovascular
      disease compared with metabolically unhealthy subjects with obesity, but they
      still have a significantly greater risk (by 50-300%) compared with metabolically 
      healthy lean subjects. Therefore, absence of metabolic risk factors in people
      with obesity should not be a contraindication for weight-loss treatment.
      Metabolically healthy obesity needs to be treated, and this need is reinforced by
      the fact that this phenotype is not stable over time, as approximately 50% of
      these subjects will cease being metabolically healthy within approximately 10 y. 
      Intervening early is therefore important. Weight loss dose-dependently decreases 
      visceral adipose tissue and liver fat content, and it improves multiorgan insulin
      sensitivity and beta-cell function (i.e., it beneficially affects many of the
      physiological traits of a metabolically healthy phenotype); however, weight loss 
      is very difficult to maintain. This typically results in disappointment among
      patients and hinders adherence, which is likely critical for the limited success 
      of most weight-loss treatments in the long term. On the other hand, using >/=1
      metabolic health targets in a non-weight-loss-centered treatment paradigm that
      includes prudent dietary changes and increased physical activity can serve as an 
      appropriate first goal that can help motivate patients toward the long-term goals
      of obesity treatment.
CI  - Copyright (c) American Society for Nutrition 2019.
FAU - Magkos, Faidon
AU  - Magkos F
AD  - Department of Nutrition, Exercise, and Sports, University of Copenhagen,
      Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
SB  - AIM
SB  - IM
OTO - NOTNLM
OT  - cardiovascular disease
OT  - diabetes
OT  - excess weight
OT  - metabolically normal obesity
OT  - risk
EDAT- 2019/06/27 06:00
MHDA- 2019/06/27 06:00
CRDT- 2019/06/27 06:00
PHST- 2019/05/01 00:00 [received]
PHST- 2019/06/06 00:00 [accepted]
PHST- 2019/06/27 06:00 [pubmed]
PHST- 2019/06/27 06:00 [medline]
PHST- 2019/06/27 06:00 [entrez]
AID - 5523188 [pii]
AID - 10.1093/ajcn/nqz133 [doi]
PST - ppublish
SO  - Am J Clin Nutr. 2019 Sep 1;110(3):533-539. doi: 10.1093/ajcn/nqz133.